Literature DB >> 15072112

Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients.

Joëlle A Erkens1, Olaf H Klungel, Ronald P Stolk, José A Spoelstra, Diederick E Grobbee, Hubert G M Leufkens.   

Abstract

PURPOSE: The objective of this study was to determine the association between different antihypertensive drug therapies and lower extremity amputations (LEAs) in type 2 diabetes patients.
METHODS: Data were obtained from the PHARMO Record Linkage System comprising pharmacy records and data on hospitalisations for all 450,000 residents of eight Dutch cities. In a nested case-control study among 12,140 type 2 diabetes patients who used antihypertensive drugs, 26 cases with a first LEA and 94 controls without a LEA matched on age, sex and calendar time were identified. Logistic regression was used to estimate the relative risk of LEA and to adjust for potential confounding factors.
RESULTS: Among type 2 diabetes patients who used antihypertensive drugs, subjects who used thiazide diuretics, alone or in combination, had a higher risk of LEA compared to subjects who used Angiotensin Converting Enzyme (ACE) inhibitor monotherapy (crude odds ratio (OR): 6.11 [95% confidence interval (CI): 1.32-28.27]). The use of thiazide diuretics was also associated with an increased risk of LEA when compared to the use of any non-thiazide antihypertensive drug (adjusted OR: 7.04 [1.10-45.30]). The increased risk of LEA associated with the use of thiazides compared to the use of non-thiazides depended on the duration of use (adjusted OR(< or = 365 days), 4.82 [0.61-38.34] and adjusted OR(>365 days), 26.16 [1.02-674.02], p-trend = 0.01).
CONCLUSIONS: Treatment with thiazide diuretics compared to treatment with other antihypertensive drugs was associated with excess amputations in type 2 diabetes patients. Due to several limitations of this study, our findings do not preclude the use of thiazides in type 2 diabetes mellitus patients as yet.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072112     DOI: 10.1002/pds.932

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  10 in total

1.  Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use.

Authors:  Louis Potier; Ronan Roussel; Gilberto Velho; Pierre-Jean Saulnier; Anisoara Bumbu; Odette Matar; Fabrice Schneider; Stéphanie Ragot; Michel Marre; Kamel Mohammedi; Samy Hadjadj
Journal:  Diabetologia       Date:  2019-02-26       Impact factor: 10.122

Review 2.  Canagliflozin: A Review in Type 2 Diabetes.

Authors:  Emma D Deeks; André J Scheen
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 3.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690

4.  The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetes.

Authors:  David J Margolis; Ole Hoffstad; Stephen Thom; Warren Bilker; Arturo R Maldonado; Robert M Cohen; Bruce J Aronow; Timothy Crombleholme
Journal:  Wound Repair Regen       Date:  2010 Sep-Oct       Impact factor: 3.617

5.  SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis.

Authors:  Louis Potier; Kamel Mohammedi; Gilberto Velho; Ronan Roussel
Journal:  Cardiovasc Diabetol       Date:  2021-05-13       Impact factor: 9.951

6.  Prognostic significance of reverse dipping status on lower limb event in type 2 diabetic patients without peripheral arterial disease.

Authors:  Pascal Delsart; Madleen Lemaitre; Anne Vambergue; Sandro Ninni; Christophe Bauters; Guillaume Ledieu; Diane-Flore Eymard; Florence Baudoux; Agathe Le Chevalier De Preville; Jonathan Sobocinski; David Montaigne; Claire Mounier-Vehier
Journal:  Acta Diabetol       Date:  2022-03-25       Impact factor: 4.280

7.  Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis.

Authors:  James Heyward; Omar Mansour; Lily Olson; Sonal Singh; G Caleb Alexander
Journal:  PLoS One       Date:  2020-06-05       Impact factor: 3.240

8.  SGLT2 inhibitors and lower limb complications: an updated meta-analysis.

Authors:  Chu Lin; Xingyun Zhu; Xiaoling Cai; Wenjia Yang; Fang Lv; Lin Nie; Linong Ji
Journal:  Cardiovasc Diabetol       Date:  2021-04-28       Impact factor: 9.951

Review 9.  Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research.

Authors:  Amber L Beitelshees; Bruce R Leslie; Simeon I Taylor
Journal:  Diabetes       Date:  2019-06       Impact factor: 9.461

10.  Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.

Authors:  Michael Fralick; Seoyoung C Kim; Sebastian Schneeweiss; Brendan M Everett; Robert J Glynn; Elisabetta Patorno
Journal:  BMJ       Date:  2020-08-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.